<p>Humacyte, Inc.（納斯達克代碼：HUMA - 獲取免費報告）內部人士 Shamik J. Parikh 於 4 月 10 日星期四購買了 7,500 股該股票。每股平均購買價格為 1.55 美元，總交易額為 11,625.00 美元。購買完成後，該內部人士現在直接擁有 7,500 股公司股票，價值約為 11,625 美元。這筆交易代表了他們對該股票的持有量增加了∞。該交易已在向美國證券交易委員會（SEC）的備案中披露，具體內容可通過此鏈接查看。</p>
<h2>Humacyte 股價上漲 2.9%</h2>
<p>在週一的交易中，HUMA 股票上漲 0.05 美元，達到 1.58 美元。該股票成交量為 1,142,258 股，而其平均成交量為 3,554,488 股。該股票的市值為 2.2813 億美元，市盈率為-1.18，貝塔值為 1.62。Humacyte, Inc.的股價在過去一年內最低為 1.15 美元，最高為 9.97 美元。該公司的 50 日簡單移動平均線為 2.87 美元，200 日簡單移動平均線為 4.16 美元。</p>
<p>Humacyte（納斯達克代碼：HUMA - 獲取免費報告）最近一次公佈財報是在 3 月 28 日星期五。該公司報告本季度每股收益（EPS）為-0.16 美元，超出市場共識預期的-0.23 美元，超出幅度為 0.07 美元。該季度的營業收入為 723 萬美元，而分析師預期為 64 萬美元。整體來看，分析師預測 Humacyte, Inc.在當前財政年度的每股收益為-1.27 美元。</p>
<h2>華爾街分析師觀點</h2>
<p>HUMA 已成為多份研究報告的主題。D. Boral Capital 在 3 月 26 日星期三的研究報告中重申了對 Humacyte 的 “買入” 評級，並設定了 25.00 美元的目標價。HC Wainwright 在 3 月 12 日星期三的研究報告中重申了對 Humacyte 的 “買入” 評級，併發布了 15.00 美元的目標價。最後，Benchmark 在 2 月 27 日星期四的研究報告中重申了對 Humacyte 的 “買入” 評級。一位股票研究分析師對該股票給予了持有評級，六位分析師給予了買入評級，一位分析師給予了強烈買入評級。根據 MarketBeat.com 的數據，該股票目前的共識評級為 “買入”，共識目標價為 13.71 美元。</p>
<p><strong>查看我們最新的 Humacyte 股票報告</strong></p>
<h2>Humacyte 的機構交易</h2>
<p>幾家大型投資者最近對 HUMA 的持倉進行了調整。Woodline Partners LP 在第四季度將其在 Humacyte 的持股增加了 235.7%。Woodline Partners LP 現在擁有 2,848,802 股公司股票，價值 1,438.6 萬美元，此前在上個季度又購買了 2,000,268 股。State Street Corp 在第三季度將其在 Humacyte 的持倉增加了 66.1%。State Street Corp 現在擁有 4,764,155 股公司股票，價值 2,591.7 萬美元，此前在上個季度又收購了 1,895,529 股。CenterBook Partners LP 在第四季度購買了 Humacyte 的新頭寸，價值約 646.3 萬美元。Brevan Howard Capital Management LP 在第四季度將其在 Humacyte 的持倉增加了 2,795.1%。Brevan Howard Capital Management LP 現在擁有 876,340 股公司股票，價值 442.6 萬美元，此前在上個季度又購買了 846,070 股。最後，Vanguard Group Inc.在第四季度將其在 Humacyte 的持股增加了 10.8%。Vanguard Group Inc.現在擁有 5,602,684 股公司股票，價值 2,829.4 萬美元，此前在上個季度又購買了 543,995 股。機構投資者持有公司 44.71% 的股票。</p>
<h2>關於 Humacyte</h2>
<p>（獲取免費報告）</p>
<p>Humacyte, Inc.從事開發和製造現成的、可植入的生物工程人類組織，以治療多種解剖部位的疾病和狀況。該公司利用其專有的科學技術平台，工程化和製造人類無細胞血管（HAV），以便植入患者體內而不引發外來物體反應或導致免疫排斥。</p>
<h2>瞭解更多</h2>
<ul>
<li>我們更看好的五隻股票，勝過 Humacyte</li>
<li>3 只最佳金融科技股票，助力投資組合提升</li>
<li>第一季度內部人士購買的三隻大型股：買入、賣出或持有</li>
<li>醫療保健股票解析：為什麼你可能想要投資</li>
<li>3 只熱銷新 IPO，逆勢而上，抵禦 2025 年市場下滑</li>
<li>如何最有效地使用 MarketBeat 財報篩選器</li>
<li>3 只高收益分紅股票，當前交易價格折扣</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SFVNQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SFVNQQ"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Humacyte 嗎？</h2>
<p>在你考慮 Humacyte 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議現在購買，以便在更廣泛的市場注意到之前...而 Humacyte 並不在名單上。</p>
<p>雖然 Humacyte 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

HUMA

<p>Shamik J. Parikh，Humacyte, Inc.（NASDAQ:HUMA）的內部人士，於 4 月 10 日以每股 1.55 美元的價格購買了 7,500 股，總計 11,625 美元。這次收購增加了他在公司的持股比例。交易後，HUMA 的股價上漲了 2.9%，達到 1.58 美元。Humacyte 報告的季度每股收益為（0.16 美元），超出預期，收入為 723 萬美元。分析師維持一致的 “買入” 評級，目標價為 13.71 美元。機構投資者持有 Humacyte 44.71% 的股份，反映出對該公司的顯著興趣</p>

<p>Humacyte, Inc. (NASDAQ:HUMA - Get Free Report) insider Shamik J. Parikh purchased 7,500 shares of the stock in a transaction that occurred on Thursday, April 10th. The shares were purchased at an average price of $1.55 per share, for a total transaction of $11,625.00. Following the completion of the purchase, the insider now directly owns 7,500 shares of the company's stock, valued at approximately $11,625. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.</p>
<div class="lb-trans"><p>Humacyte, Inc.（納斯達克代碼：HUMA - 獲取免費報告）內部人士 Shamik J. Parikh 於 4 月 10 日星期四購買了 7,500 股該股票。每股平均購買價格為 1.55 美元，總交易額為 11,625.00 美元。購買完成後，該內部人士現在直接擁有 7,500 股公司股票，價值約為 11,625 美元。這筆交易代表了他們對該股票的持有量增加了∞。該交易已在向美國證券交易委員會（SEC）的備案中披露，具體內容可通過此鏈接查看。</p>
</div><h2>Humacyte Trading Up 2.9 %</h2>
<div class="lb-trans"><h2>Humacyte 股價上漲 2.9%</h2>
</div><p>HUMA stock traded up $0.05 during trading on Monday, hitting $1.58. 1,142,258 shares of the stock traded hands, compared to its average volume of 3,554,488. The stock has a market cap of $228.13 million, a price-to-earnings ratio of -1.18 and a beta of 1.62. Humacyte, Inc. has a one year low of $1.15 and a one year high of $9.97. The company has a 50 day simple moving average of $2.87 and a 200 day simple moving average of $4.16.</p>
<div class="lb-trans"><p>在週一的交易中，HUMA 股票上漲 0.05 美元，達到 1.58 美元。該股票成交量為 1,142,258 股，而其平均成交量為 3,554,488 股。該股票的市值為 2.2813 億美元，市盈率為-1.18，貝塔值為 1.62。Humacyte, Inc.的股價在過去一年內最低為 1.15 美元，最高為 9.97 美元。該公司的 50 日簡單移動平均線為 2.87 美元，200 日簡單移動平均線為 4.16 美元。</p>
</div><p>Humacyte (NASDAQ:HUMA - Get Free Report) last announced its earnings results on Friday, March 28th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.07. The business had revenue of $7.23 million during the quarter, compared to analyst estimates of $0.64 million. As a group, analysts predict that Humacyte, Inc. will post -1.27 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Humacyte（納斯達克代碼：HUMA - 獲取免費報告）最近一次公佈財報是在 3 月 28 日星期五。該公司報告本季度每股收益（EPS）為-0.16 美元，超出市場共識預期的-0.23 美元，超出幅度為 0.07 美元。該季度的營業收入為 723 萬美元，而分析師預期為 64 萬美元。整體來看，分析師預測 Humacyte, Inc.在當前財政年度的每股收益為-1.27 美元。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><p>HUMA has been the topic of a number of research reports. D. Boral Capital restated a &#34;buy&#34; rating and set a $25.00 price objective on shares of Humacyte in a research report on Wednesday, March 26th. HC Wainwright restated a &#34;buy&#34; rating and issued a $15.00 price objective on shares of Humacyte in a research note on Wednesday, March 12th. Finally, Benchmark reiterated a &#34;buy&#34; rating on shares of Humacyte in a research report on Thursday, February 27th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of &#34;Buy&#34; and a consensus price target of $13.71.</p>
<div class="lb-trans"><p>HUMA 已成為多份研究報告的主題。D. Boral Capital 在 3 月 26 日星期三的研究報告中重申了對 Humacyte 的 “買入” 評級，並設定了 25.00 美元的目標價。HC Wainwright 在 3 月 12 日星期三的研究報告中重申了對 Humacyte 的 “買入” 評級，併發布了 15.00 美元的目標價。最後，Benchmark 在 2 月 27 日星期四的研究報告中重申了對 Humacyte 的 “買入” 評級。一位股票研究分析師對該股票給予了持有評級，六位分析師給予了買入評級，一位分析師給予了強烈買入評級。根據 MarketBeat.com 的數據，該股票目前的共識評級為 “買入”，共識目標價為 13.71 美元。</p>
</div><p><strong>Check Out Our Latest Stock Report on Humacyte</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的 Humacyte 股票報告</strong></p>
</div><h2>Institutional Trading of Humacyte</h2>
<div class="lb-trans"><h2>Humacyte 的機構交易</h2>
</div><p>Several large investors have recently made changes to their positions in HUMA. Woodline Partners LP raised its holdings in shares of Humacyte by 235.7% in the fourth quarter. Woodline Partners LP now owns 2,848,802 shares of the company's stock valued at $14,386,000 after buying an additional 2,000,268 shares during the last quarter. State Street Corp increased its position in Humacyte by 66.1% in the 3rd quarter. State Street Corp now owns 4,764,155 shares of the company's stock valued at $25,917,000 after acquiring an additional 1,895,529 shares in the last quarter. CenterBook Partners LP bought a new position in shares of Humacyte in the fourth quarter worth about $6,463,000. Brevan Howard Capital Management LP lifted its position in shares of Humacyte by 2,795.1% during the fourth quarter. Brevan Howard Capital Management LP now owns 876,340 shares of the company's stock worth $4,426,000 after purchasing an additional 846,070 shares in the last quarter. Finally, Vanguard Group Inc. grew its stake in shares of Humacyte by 10.8% during the fourth quarter. Vanguard Group Inc. now owns 5,602,684 shares of the company's stock valued at $28,294,000 after purchasing an additional 543,995 shares during the last quarter. Institutional investors own 44.71% of the company's stock.</p>
<div class="lb-trans"><p>幾家大型投資者最近對 HUMA 的持倉進行了調整。Woodline Partners LP 在第四季度將其在 Humacyte 的持股增加了 235.7%。Woodline Partners LP 現在擁有 2,848,802 股公司股票，價值 1,438.6 萬美元，此前在上個季度又購買了 2,000,268 股。State Street Corp 在第三季度將其在 Humacyte 的持倉增加了 66.1%。State Street Corp 現在擁有 4,764,155 股公司股票，價值 2,591.7 萬美元，此前在上個季度又收購了 1,895,529 股。CenterBook Partners LP 在第四季度購買了 Humacyte 的新頭寸，價值約 646.3 萬美元。Brevan Howard Capital Management LP 在第四季度將其在 Humacyte 的持倉增加了 2,795.1%。Brevan Howard Capital Management LP 現在擁有 876,340 股公司股票，價值 442.6 萬美元，此前在上個季度又購買了 846,070 股。最後，Vanguard Group Inc.在第四季度將其在 Humacyte 的持股增加了 10.8%。Vanguard Group Inc.現在擁有 5,602,684 股公司股票，價值 2,829.4 萬美元，此前在上個季度又購買了 543,995 股。機構投資者持有公司 44.71% 的股票。</p>
</div><h2>About Humacyte</h2>
<div class="lb-trans"><h2>關於 Humacyte</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.</p>
<div class="lb-trans"><p>Humacyte, Inc.從事開發和製造現成的、可植入的生物工程人類組織，以治療多種解剖部位的疾病和狀況。該公司利用其專有的科學技術平台，工程化和製造人類無細胞血管（HAV），以便植入患者體內而不引發外來物體反應或導致免疫排斥。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than Humacyte</li>
<li>3 Best Fintech Stocks for a Portfolio Boost</li>
<li>Top 3 Large Cap Stocks Insiders Bought in Q1: Buy, Sell, or Hold</li>
<li>Health Care Stocks Explained: Why You Might Want to Invest</li>
<li>3 Hot New IPOs Defying the 2025 Market Slump</li>
<li>How to Most Effectively Use the MarketBeat Earnings Screener</li>
<li>3 High-Yield Dividend Stocks Trading at a Discount</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過 Humacyte</li>
<li>3 只最佳金融科技股票，助力投資組合提升</li>
<li>第一季度內部人士購買的三隻大型股：買入、賣出或持有</li>
<li>醫療保健股票解析：為什麼你可能想要投資</li>
<li>3 只熱銷新 IPO，逆勢而上，抵禦 2025 年市場下滑</li>
<li>如何最有效地使用 MarketBeat 財報篩選器</li>
<li>3 只高收益分紅股票，當前交易價格折扣</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SFVNQQ" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=HUMA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Humacyte Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Humacyte 嗎？</h2>
</div><p>Before you consider Humacyte, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Humacyte 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humacyte wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議現在購買，以便在更廣泛的市場注意到之前...而 Humacyte 並不在名單上。</p>
</div><p>While Humacyte currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Humacyte 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Shamik J. Parikh 購買了 7,500 股 Humacyte, Inc.（NASDAQ:HUMA）的股票